Overview

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients

Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The Olanzapine Regimen will be superior to the Standard Regimen, as measured by the proportion of patients with Complete Response in the 120 hours following AC chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
CCTU
Treatments:
Aprepitant
BB 1101
Dexamethasone
Dexamethasone acetate
Fosaprepitant
Olanzapine
Ondansetron